Zenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings Results

Zenas BioPharma (NASDAQ:ZBIO) released its earnings results on Monday. The company reported ($4.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32), FiscalAI reports.

Zenas BioPharma Trading Down 3.4%

NASDAQ ZBIO opened at $23.23 on Tuesday. Zenas BioPharma has a one year low of $6.11 and a one year high of $44.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The firm has a market cap of $1.25 billion, a P/E ratio of -3.29 and a beta of -1.96. The stock’s 50-day moving average is $22.61 and its 200-day moving average is $27.12.

Insider Activity at Zenas BioPharma

In other Zenas BioPharma news, Director Hongbo Lu bought 25,985 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was acquired at an average cost of $22.50 per share, with a total value of $584,662.50. Following the purchase, the director owned 347,968 shares in the company, valued at $7,829,280. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patricia L. Allen bought 15,700 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were bought at an average price of $24.85 per share, for a total transaction of $390,145.00. Following the completion of the acquisition, the director directly owned 15,700 shares in the company, valued at approximately $390,145. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 202,845 shares of company stock worth $3,747,185. 16.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP lifted its position in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Zenas BioPharma in the 3rd quarter worth $30,000. BNP Paribas Financial Markets increased its holdings in Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in Zenas BioPharma during the 4th quarter worth about $227,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of Zenas BioPharma in the 4th quarter valued at about $238,000.

Key Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company secured up to $250 million in non-dilutive, multi‑tranche debt financing from Pharmakon to support development and commercialization plans—improves near-term liquidity and reduces immediate dilution risk. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Regulatory milestones: Zenas expects to file obexelimab marketing applications for IgG4‑RD with the FDA in Q2 2026 and with the EMA in H2 2026; SunStone SLE topline is due Q4 2026 — these near‑term milestones can materially re‑rate the stock if positive. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Insider and institutional buying highlighted in recent data (multiple insiders and funds increased stakes), which can signal confidence from management and large holders. Quiver Quant — Inducement Grants (also shows insider activity)
• Neutral Sentiment: Morgan Stanley analyst Judah Frommer maintained a Hold and raised the price target to $21 — the raise is supportive, but the PT remains below some prior analyst targets and near current trading levels, signaling mixed analyst sentiment. TipRanks — Morgan Stanley Rating
• Neutral Sentiment: Company granted inducement stock options (235,700 options at $23.23 and 33,450 RSUs) to new hires to aid recruitment; standard for growth-stage biotech but adds potential future dilution as awards vest. GlobeNewswire — Inducement Grants
• Negative Sentiment: Quarterly GAAP EPS missed heavily: Zenas reported a loss of $4.54 per share vs. consensus roughly -$1.22 — the magnitude of the miss drove investor concern about execution and near‑term profitability. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action expands legal risk and potential financial/operational uncertainty for the company. TipRanks — IPO-Related Securities Class Action

Analysts Set New Price Targets

A number of equities research analysts recently commented on ZBIO shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Morgan Stanley lowered Zenas BioPharma from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $37.00 to $19.00 in a research note on Monday, January 5th. Wedbush restated an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a report on Monday, December 22nd. Evercore assumed coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zenas BioPharma currently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.